DNLI - Denali Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
15.74
-0.43 (-2.66%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close16.17
Open16.14
Bid14.85 x 900
Ask16.48 x 1100
Day's Range15.52 - 16.31
52 Week Range12.32 - 25.79
Volume334,319
Avg. Volume407,635
Market Cap1.492B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.58
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.75
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    Denali Therapeutics Reports Second Quarter 2018 Financial Results

    SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018-- Denali Therapeutics Inc., a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial ...

  • GlobeNewswire17 days ago

    Denali Therapeutics Announces Positive Clinical Results From LRRK2 Inhibitor Program for Parkinson’s Disease

    Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today announced positive results from its Phase 1 clinical study with DNL201, a small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2). In a randomized, double blind, placebo-controlled, oral dose study in healthy subjects, DNL201 achieved its safety, pharmacokinetic, and pharmacodynamic objectives.

  • With new attack on Alzheimer's, this young biotech is hiring, grabbing more space
    American City Business Journals26 days ago

    With new attack on Alzheimer's, this young biotech is hiring, grabbing more space

    Alector is developing drugs that target the immune system in the brain, much like cancer immunotherapy drugs have shown success in boosting the body's immune system against tumors.

  • GlobeNewswire3 months ago

    Denali Therapeutics Announces Early Exercise of Its Option to Acquire F-star Gamma

    Denali Therapeutics Inc. (DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it has exercised its option to acquire all outstanding shares in F-star Gamma pursuant to the Option Agreement dated August 24, 2016 and expanded its collaboration with F-star on Denali’s biologics Transport Vehicle (“TV”) blood-brain barrier (“BBB”) platform technology. Denali entered into a License and Collaboration Agreement with F-star in August 2016 to support the development of and provide rights to intellectual property for Denali’s proprietary TV platform technology to deliver therapeutics across the BBB.

  • 'Bursting at the seams,' this high-profile Peninsula biotech company is moving to a bigger home
    American City Business Journals3 months ago

    'Bursting at the seams,' this high-profile Peninsula biotech company is moving to a bigger home

    Five years after the company started and two years after it moved into the new biotech lab-office project at Highway 101 and Oyster Point Boulevard, this company with experimental drugs in Alzheimer's, Parkinson's and ALS will quadruple its space.

  • Why Denali Therapeutics (DNLI) Could Shock the Market Soon
    Zacks4 months ago

    Why Denali Therapeutics (DNLI) Could Shock the Market Soon

    Denali Therapeutics (DNLI) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

  • TheStreet.com5 months ago

    Here's When You Can Buy Twitter's Stock

    There just aren't any pockets of strong momentum right now.

  • Takeda and Denali Therapeutics Collaborate to Develop and Commercialize Therapies for Neurodegenerative Diseases
    Business Wire7 months ago

    Takeda and Denali Therapeutics Collaborate to Develop and Commercialize Therapies for Neurodegenerative Diseases

    Takeda Pharmaceutical Company Limited and Denali Therapeutics today announced that they have entered into a strategic option and collaboration agreement to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases.

  • Benzinga7 months ago

    Analyst: Denali Therapeutics' Neuroscience Work Could Lead To Near-Term Upside

    A Morgan Stanley analyst predicts near-term upside for the shares of Denali Therapeutics Inc. (NASDAQ: DNLI ), thanks to its work in neuroscience and particularly its lead programs in Parkinson's and Alzheimer's. ...

  • Benzinga7 months ago

    3 Key Questions For Denali Therapeutics Investors

    Denali Therapeutics Inc. (NASDAQ: DNLI ), a biotech company focusing on therapies for neurodegenerative disorders,  IPO-ed in Dec. 2017, offering 13.9 million shares at $18 each.  The Analyst Goldman Sachs ...

  • American City Business Journals8 months ago

    Redwood City biopharma startup hopes to raise up to $98M in what could be Bay Area's first IPO of 2018

    Menlo Therapeutics Inc. filed Thursday to raise up to about $98 million in what could be the first IPO of the New Year from the Bay Area. South San Francisco-based Denali Therapeutics Inc. (DNLI) raised $229 million earlier this month and San Jose-based Restoration Robotics (HAIR) raised $25 million in mid-October. Menlo Therapeutics started out in 2011 under the name Tigercat Pharma Inc. and changed its name to Menlo Therapeutics in May 2016. It has raised about $110 million in funding, including a July round of $50 million this year that gave it a valuation of about $210 million, according to PitchBook Data.

  • 24/7 Wall St.8 months ago

    Denali Therapeutics Enters the Market With a Bang

    Denali Therapeutics entered the markets with a bang on Friday. In its initial public offering, the company priced its almost 14 million shares within the expected range.